Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR3 |
| Variant | G380E |
| Impact List | missense |
| Protein Effect | gain of function - predicted |
| Gene Variant Descriptions | FGFR3 G380E lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). G380E results in a growth advantage in a competition assay and increased transformation activity in cultured cells (PMID: 34272467), and therefore, is predicted to lead to a gain of Fgfr3 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR3 mutant FGFR3 act mut FGFR3 G380E |
| Transcript | NM_000142.5 |
| gDNA | chr4:g.1804393G>A |
| cDNA | c.1139G>A |
| Protein | p.G380E |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_047449824.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_011513422.2 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_047449823.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| NM_000142.4 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_011513420.2 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_047449822.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_006713873.2 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| NM_001354810.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| NM_001354809.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_011513420.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| NM_000142.5 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_006713873.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| XM_011513422.1 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| NM_001354810.2 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| NM_001354809.2 | chr4:g.1804393G>A | c.1139G>A | p.G380E | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 G380E | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3 G380E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR3 G380E | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3 G380E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR3 G380E | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3 G380E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
| FGFR3 G380E | Advanced Solid Tumor | predicted - resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR3 G380E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |